Sanofi us enters into co-promotion agreement with provention bio, inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

Sanofi us to co-promote teplizumab, adding it to its current commercial activities in diabetes care, leveraging its existing best-in-class customer-facing field teams provention bio, inc. retains all rights to teplizumab commercialization activities are dependent on u.s. fda approval of teplizumab, potentially on november 17, 2022 bridgewater, n.j. , oct. 6, 2022 /prnewswire/ -- sanofi us has announced it has entered into a co-promotion service agreement with provention bio, inc., for the commercialization of teplizumab in the united states.
PRVB Ratings Summary
PRVB Quant Ranking